Dr. Daniel Bucks, Director of the skin biology and drug delivery laboratory at Dow Pharmaceutical Sciences, speaks on skin permeation enhancement techniques at AAPS convention in Baltimore 
PETALUMA, CA – December 8th 2004: PETALUMA, CA – Dr. Daniel Bucks, Director of Skin Biology and Drug Delivery at Dow Pharmaceutical Sciences, presented “Skin Permeation Enhancement by Controlled Abrasion and Stratum Corneum Stripping” at an AAPS roundtable on November 8th, 2004. The round table, entitled “Unique Methods for Enhancing Drug Penetration and Permeation into and Through the Skin,” was sponsored by the Dermatopharmaceutics Focus Group of the American Association of Pharmaceutical Scientists (AAPS) and was attended by over 200 members who came together to present and discuss various techniques and technologies for enhancing skin permeation.

In his presentation, Dr. Bucks stated that many chemical and physical strategies used in the past generally have not fulfilled their promise to enhance penetration. However, physical techniques, including needle scoring, tape stripping and sand paper abrasion are less complicated, less expensive, and create a more controlled environment for producing positive results. Dr. Bucks concluded that continued development of these physical disruption techniques will increase the standard knowledge of permeation enhancement and eventually will lead to more cost effective means to enhance skin permeation.

Dr. Bucks manages the Skin Biology and Drug Delivery Department at Dow Pharmaceutical Sciences, a Petaluma, California company that specializes in development of ethical topical drug products for pharmaceutical and biotechnology clients, including early stage consultation. Formulations are optimized using release and permeation studies conducted in Dow’s Skin Biology and Drug Delivery Laboratory. Dow also provides regulatory strategy development, non-clinical and clinical study design and management, and regulatory filings required to take dermatology products from inception through FDA approval.

For more information please visit www.dowpharmsci.com